Microbiota-Immune Interactions in Ulcerative Colitis and Colitis Associated Cancer and Emerging Microbiota-Based Therapies

International Journal of Molecular Sciences

David Avelar Rodriguez¹  Valentina Caputi²  Nikhil Pai³  Jelena Popov³  Nandini Nandeesha⁴ 

[1] Department of Pediatrics, University of Toronto, Toronto, ON M5S 1A1, Canada;Department of Poultry Science, University of Arkansas, Fayetteville, AR 72701, USA;Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, McMaster University, Hamilton, ON L8S 4L8, Canada;School of Medicine, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland;

关键词: ulcerative colitis;    inflammatory bowel diseases;    pediatrics;    FMT;    probiotics;    synbiotics;   

DOI  :  10.3390/ijms222111365

来源: DOAJ

【 摘 要 】

Ulcerative colitis (UC) is a chronic autoimmune disorder affecting the colonic mucosa. UC is a subtype of inflammatory bowel disease along with Crohn’s disease and presents with varying extraintestinal manifestations. No single etiology for UC has been found, but a combination of genetic and environmental factors is suspected. Research has focused on the role of intestinal dysbiosis in the pathogenesis of UC, including the effects of dysbiosis on the integrity of the colonic mucosal barrier, priming and regulation of the host immune system, chronic inflammation, and progression to tumorigenesis. Characterization of key microbial taxa and their implications in the pathogenesis of UC and colitis-associated cancer (CAC) may present opportunities for modulating intestinal inflammation through microbial-targeted therapies. In this review, we discuss the microbiota-immune crosstalk in UC and CAC, as well as the evolution of microbiota-based therapies.

【 授权许可】

Unknown